Robert Shenkar to Magnetic Resonance Imaging
This is a "connection" page, showing publications Robert Shenkar has written about Magnetic Resonance Imaging.
Connection Strength
0.904
-
Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions. Neurosurgery. 2008 Oct; 63(4):782-9; discussion 789.
Score: 0.137
-
Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery. 2008 Oct; 63(4):790-7; discussion 797-8.
Score: 0.137
-
Credulity of exploratory trials for cerebral cavernous malformations. Lancet Neurol. 2023 01; 22(1):2-3.
Score: 0.091
-
Propranolol as therapy for cerebral cavernous malformations: a cautionary note. J Transl Med. 2022 04 05; 20(1):160.
Score: 0.087
-
Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth. J Magn Reson Imaging. 2022 05; 55(5):1440-1449.
Score: 0.084
-
Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites. J Magn Reson Imaging. 2020 04; 51(4):1192-1199.
Score: 0.073
-
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging. 2018 04; 47(4):1133-1138.
Score: 0.063
-
Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping. Invest Radiol. 2014 Jul; 49(7):498-504.
Score: 0.051
-
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling. Stroke. 2024 01; 55(1):31-39.
Score: 0.025
-
COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
Score: 0.021
-
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. J Cereb Blood Flow Metab. 2021 11; 41(11):2944-2956.
Score: 0.021
-
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
Score: 0.020
-
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2021 03 01; 134(3):1147-1154.
Score: 0.019
-
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
Score: 0.019
-
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
Score: 0.015
-
Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
Score: 0.014
-
Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations. Stroke. 2014 Feb; 45(2):598-601.
Score: 0.012
-
Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery. 2009 Jul; 65(1):138-44; discussion 144-5.
Score: 0.009
-
Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke. 2005 Apr; 36(4):872-4.
Score: 0.007